Oxycodone-induced tolerance to respiratory depression:reversal by ethanol, pregabalin and protein kinase C inhibition by Hill, Rob et al.
                          Hill, R., Dewey, W. L., Kelly, E., & Henderson, G. (2018). Oxycodone-
induced tolerance to respiratory depression: reversal by ethanol, pregabalin
and protein kinase C inhibition. British Journal of Pharmacology, 175(12),
2492-2503. https://doi.org/10.1111/bph.14219
Peer reviewed version
License (if available):
CC BY-NC
Link to published version (if available):
10.1111/bph.14219
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.14219 . Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Hill et al 
 
1 
 
Oxycodone-induced Tolerance to Respiratory Depression: Reversal by Ethanol, Pregabalin, 
and Protein Kinase C Inhibition. 
Short Title: Ethanol and pregabalin reverse oxycodone tolerance 
Rob Hill1, William L Dewey2, Eamonn Kelly1 and Graeme Henderson*1 
1School of Physiology, Pharmacology & Neuroscience, University of Bristol, University Walk, 
Bristol, BS8 1TD, UK 
2Department of Pharmacology and Toxicology, Virginia Commonwealth University, William 
Dewey <william.dewey@vcuhealth.org>, Richmond, Virginia 23298-0613, USA 
 
Author for correspondence: graeme.henderson@bristol.ac.uk 
 
Financial disclosures: None 
 
Statement of Conflicts of Interest: The authors have nothing to disclose 
 
Non standard abbreviations 
AUC  area under the curve 
DOPr   opioid receptor 
KOPr   opioid receptor 
MOPr    opioid receptor 
NorBNI Norbinaltorphimine 
 
Key words 
Opioid; oxycodone; respiratory depression; tolerance; protein kinase C  
Hill et al 
 
2 
 
ABSTRACT 
Background and Purpose: 
Oxycodone, a prescription opioid, is a major drug of abuse, especially in the USA, and 
contributes significantly to opioid overdose deaths each year. Overdose deaths result 
primarily from respiratory depression. We have studied respiratory depression by oxycodone 
and have characterized how tolerance develops on prolonged exposure to the drug. We have 
investigated the role of protein kinase C (PKC) in maintaining tolerance and have examined 
whether ethanol or pregabalin reverse oxycodone-induced tolerance  
 
Experimental Approach: 
Respiration was measured in male CD-1 mice by whole body plethysmography. Mice were 
preinjected with oxycodone, then implanted with mini-pumps (s.c.) delivering 20, 45 or 120 
mg.kg-1.d-1 oxycodone for 6 d and subsequently challenged with oxycodone (3 mg.kg-1 i.p.) or 
morphine (10 mg.kg-1 i.p.) to assess the level of tolerance.  
 
Key Results:  
Oxycodone-treated mice developed tolerance to oxycodone and cross tolerance to morphine-
induced respiratory depression. Tolerance was less with 20 mg.kg-1.d-1 than with 45 or 120 
mg.kg-1.d-1 oxycodone treatment. At doses that do not depress respiration, ethanol (0.3 g.kg-
1), pregabalin (20 mg.kg-1) and calphostin C (45 µg.kg-1) all reversed oxycodone-induced 
tolerance resulting in significant respiratory depression. Reversal of tolerance was less in mice 
treated with oxycodone (120 mg.kg-1.d-1). In mice receiving ethanol and calphostin C or 
ethanol and pregabalin there was no greater reversal of tolerance than seen with either drug 
alone. 
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Conclusion and Implications: 
These data suggest that oxycodone-induced tolerance is mediated by PKC and that reversal 
of tolerance by ethanol or pregabalin may be a contributory factor in oxycodone overdose 
deaths. 
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INTRODUCTION 
Opioid overdose deaths are a prominent public health issue in many countries around the 
world. In the USA deaths involving prescription opioids and illicit heroin increased 5 fold from 
1999 to 2015 (Hedegaard et al, 2017) despite considerable efforts aimed at combating the 
problem (Okie, 2010). In 2015 the number of overdose deaths involving prescription opioids 
in the USA (~ 17,000) was greater than that from illicit heroin (~13,000). Death due to opioid 
overdose results primarily from respiratory depression (White & Irvine, 1999). Oxycodone 
(Oxycontin) is one of the most commonly prescribed opioid analgesics in the USA and forms 
a significant percentage of the hospital admissions for opioid overdose (Pfister et al., 2016) 
and prescription opioid overdose deaths (Inciardi et al., 2007, Kenan et al., 2012, Sgarlato and 
deRoux, 2015). In most instances of prescription opioid overdose other drugs such as alcohol 
and benzodiazepines were also found to be present (Sgarlato & deRoux, 2015). We and others 
have suggested that polydrug use (i.e. using other drugs such as alcohol, benzodiazepines, or 
pregabalin in addition to opioids) may increase the likelihood of opioid overdose (Darke & 
Hall, 1995, 2003; Hickman et al, 2007; Brecht et al, 2008; Hill et al, 2016; Lyndon et al, 2017).  
We have recently reported that in mice, tolerance develops to the respiratory depressant 
effects of morphine, an active metabolite of heroin (Hill et al, 2016). The tolerance induced 
by morphine was reversed by a single low dose of ethanol that itself did not induce respiratory 
depression, thus resulting in significant respiratory depression to a dose of morphine in 
otherwise morphine tolerant animals. In contrast, the tolerance induced by prolonged 
treatment with methadone was not reversed by ethanol. This may be explained by morphine 
and methadone inducing -opioid receptor (MOPr) desensitization and tolerance by different 
cellular mechanisms (for review see Williams et al, 2013). There is substantial evidence that 
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MOPr desensitization and tolerance to morphine is mediated primarily by a protein kinase C 
(PKC)-dependent mechanism (Bailey et al, 2006, 2009a, 2009b) whereas desensitization and 
tolerance to methadone is likely mediated by a G protein-coupled receptor kinase (GRK)- and 
arrestin-dependent mechanism (McPherson et al, 2010). We have recently gone on to show 
that tolerance to the respiratory-depressant effects of morphine can also be reversed by 
acute injection of the gabapentoid drug pregabalin (Lyndon et al., 2017). 
Oxycodone depresses respiration in man (Leino et al., 1999; Chang et al., 2010) and in rodents 
(Kuo et al., 2015; Whiteside et al., 2016). In the present experiments we have characterized 
the respiratory depressant effects of oxycodone in mice. We have examined whether 
prolonged oxycodone administration results in the development of tolerance to respiratory 
depression, the role of PKC in such tolerance and whether acute administration of a low dose 
of ethanol or pregabalin, drugs that may be taken by people also using oxycodone, could 
reverse oxycodone-induced tolerance.  
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METHODS AND MATERIALS 
Animals: Male CD-1 mice (Harlan Laboratories, UK) weighing approximately 30 g were group 
housed, 4 - 6 per cage and maintained at 22 °C on a reversed 12 h dark-light cycle with food 
and water available ad libitum. Experiments were performed in the dark (active) phase. A 
total of 291 mice were used in the study. All procedures were performed in accordance with 
the UK Animals (Scientific Procedures) Act 1986, the European Communities Council Directive 
(2010/63/EU) and the University of Bristol ethical review document, as well as the ARRIVE 
and British Journal of Pharmacology guidelines. 
Measurement of respiration: Respiration was measured in freely moving animals using 
plethysmography chambers (EMKA Technologies, France) supplied with a 5% CO2 in air 
mixture (BOC Gas Supplies, UK). For a detailed description of measuring respiratory function 
by whole body plethysmography see Lim et al. (2014). Animals were randomly ascribed to 
treatment groups with the experimenter blinded to drug treatment until after subsequent 
data analyses had been performed. Rate and depth of respiration were recorded and 
averaged over 5 min periods (except immediately after drug injection when the time-period 
was 3 min) and converted to minute volume (rate x tidal volume). Data are presented both as 
minute volume and as percentage change from the pre-drug minute volume baseline, 
calculated for each mouse individually before mean data were plotted. Presenting data as 
percentage change from the pre-drug levels has been performed to control for variation 
between treatment groups that may have different baseline levels of respiration. In our 
experience variation in baseline respiration levels do not influence the extent of opioid 
depression of respiration (Hill & Henderson, 2017, unpublished data).  
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Data from previous experiments where respiratory depression was measured either following 
acute opioid administration in naïve mice or following pump implantation were subjected to 
post hoc power analyses using G*Power (version 3.1.9). Our calculations indicated that n=6 
(acute experiments) or n=7 (pump experiments) for each individual group would produce a 
significant result if an actual effect occurred. 
The acute effects of opioid agonists (oxycodone, morphine and U69593) on respiration 
(minute volume) were monitored for 30 min following drug administration. The opioid 
antagonists naloxone, naltrindole and norbinaltorphimine (NorBNI) were administered 30 
min prior to the opioid agonists. 
Induction of opioid tolerance: We have previously reported that in the mouse tolerance to 
the respiratory depressant effects of morphine did not develop with repeated twice daily 
doses of morphine (Hill et al., 2016) but did develop with continuous administration of 
morphine from either a morphine pellet or a subcutaneously implanted osmotic mini-pump 
(Withey et al., 2017). Oxycodone is metabolized more rapidly in rodents than in man (Raehal 
and Bohn, 2011). In the present experiments oxycodone tolerance was induced by priming 
mice with three i.p. injections of oxycodone at 12 h intervals followed by subcutaneous 
implantation on the dorsal flank of an osmotic mini-pump (ALZET®) containing oxycodone for 
6 days. This follows the protocol first described for induction of opioid tolerance in mice by 
Quillinan et al., (2011). Implantation of osmotic mini-pumps was done under isoflurane 
general anaesthesia. Three schedules of oxycodone treatment were used:- 
(i) Low dose treatment – 3 x 30 mg.kg-1 i.p injections at 12 h intervals followed by 6 
days of 20 mg.kg-1.d-1 s.c. The oxycodone dosing is based on the relative potency 
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of oxycodone and morphine to depress respiration in mice (see Fig. 1) and the 
protocol described by Withey et al., (2017) for induction of morphine tolerance. 
(ii) Moderate dose treatment – 3 x 100 mg.kg-1 i.p injections at 12 h intervals followed 
by 6 days of 45 mg.kg-1.d-1 s.c.. In this treatment, the doses of oxycodone are the 
same as the doses morphine used by Withey et al., (2017). 
(iii) High dose treatment – 3 x 100 mg.kg-1 i.p injections at 12 h intervals followed by 6 
days of 120 mg.kg-1.d-1 s.c. In this treatment, the daily dose of oxycodone released 
from the pump has been increased six-fold from the low dose treatment. 
Assessment of opioid tolerance: To assess the level of tolerance induced by the oxycodone 
treatments, mice were injected on day 6 following oxycodone pump implantation with a 
challenge dose of morphine (10 mg.kg-1 i.p.) or oxycodone (3 mg.kg-1 i.p.) and respiration 
monitored for 30 min. The degree of respiratory depression observed in opioid-treated 
animals was compared to that observed in control animals that had received saline priming 
injections and been implanted with saline filled osmotic mini-pumps rather than opioid drug 
and which had been challenged with morphine (10 mg.kg-1 i.p.). We used the same morphine 
challenge to assess oxycodone-induced tolerance as we have used in previous studies of 
tolerance induced by prolonged morphine and methadone treatments (Hill et al., 2016; 
Withey et al., 2017; Lyndon et al., 2017) in order that the levels of tolerance induced by 
different opioids can be directly compared. In addition, we have also used an oxycodone 
challenge to determine the degree of tolerance that prolonged oxycodone treatment induces 
to oxycodone itself. 
Reversal of tolerance: The ability of ethanol (0.3 g.kg-1 i.p.), pregabalin (20 mg.kg-1 i.p.) and 
calphostin C (45 µg.kg-1 i.p.) to reverse tolerance to respiratory depression induced by 
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prolonged oxycodone treatment was investigated. Ethanol and pregabalin were administered 
simultaneously with the acute morphine challenge whereas calphostin C was administered as 
a pre-treatment 30 min before the acute morphine challenge. In control experiments the 
appropriate vehicle was injected with the morphine challenge. 
Measurement of Brain and Plasma Oxycodone Levels: Mice were killed using escalating 
CO2 and blood samples collected from the descending abdominal aorta. Blood samples 
were centrifuged at 3000 g for 10 min at 4°C and the aliquoted plasma supernatant stored 
at −20°C. Immediately after blood sampling, mice were decapitated and the head placed 
on ice. After removal from the skull, the brains were flash frozen in liquid nitrogen before 
storage at −80°C. Subsequently plasma and brain levels of oxycodone were measured by gas 
chromatography mass spectrometry analysis at the Virginia Commonwealth University 
(Richmond, VA, USA) by the method described in Jacob et al. (2017). 
Data Analysis: Area under the curve (AUC) was determined using a 100% baseline as 
described previously (Hill et al., 2016). Overall changes from a single factor were analyzed 
using a One-way ANOVA with Bonferroni’s post-test. Interaction between prolonged drug 
treatment and challenge drug was analysed using a Two-way ANOVA in a two-by-two 
factorial. Changes in groups over time with repeat measurements were analysed using a Two-
way repeated measures ANOVA with Bonferroni’s post-test to analyse drug effect over time. 
GraphPad Prism 5 was used for all statistical analyses. All data are displayed as mean ± 
standard error of the mean (SEM). The data and statistical analyses comply with the 
recommendations on experimental design and analysis in pharmacology (Curtis et al. 2015). 
Drugs and chemicals 
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Morphine hydrochloride (Macfarlane Smith), naloxone hydrochloride, naltrindole 
hydrochloride, norbinaltorphimine dihydrochloride, oxycodone hydrochloride and (+)-
(5α,7α,8β)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide 
(U69593) (all from Sigma Aldrich, UK) as well as S-pregabalin (extracted and purified from 
Lyrica tablets by Dr Erica Burnell, University of Bristol) were dissolved in sterile saline. Ethanol 
(Sigma Aldrich, UK) was diluted in sterile saline. Calphostin C (Tocris, UK) was dissolved in 
100% dimethyl sulfoxide (DMSO) and diluted in distilled water such that the final 
concentration of DMSO was 0.5%.  
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a, 2017b).   
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RESULTS 
Comparison of the respiratory depressant effects of oxycodone and morphine 
We have previously demonstrated the respiratory depressant effect of morphine (3 and 10 
mg.kg-1 i.p.) in mice breathing 5% CO2 in air (Hill et al., 2016). Acute administration of 
oxycodone (1 or 3 mg.kg-1 i.p.) produced dose-dependent depression of respiration (Fig. 1A, 
B, E, G). Oxycodone was slightly more potent in depressing respiration than morphine, in that  
3 mg.kg-1 oxycodone produced a similar degree of respiratory depression as that to 10 mg.kg-
1 morphine (Fig. 1G). No mice were insensitive to the respiratory depressant effects of 
oxycodone at the doses tested (Fig. 1G). The depression of respiration by oxycodone resulted 
from a decrease in the rate of respiration (control rate 550 ± 33 breaths per min versus 291 ± 
22 breaths per min at the peak of inhibition by oxycodone 3 mg.kg-1) (Student’s unpaired T-
test, t=6.50, dfn=10, P<0.05), rather than a decrease in tidal volume (control tidal volume 0.29 
± 0.02 ml.min-1 versus 0.28 ± 0.01 ml.min-1 at the peak of inhibition by oxycodone mg.kg-1) 
(Student’s unpaired T-test, t=0.45, dfn=10, P<0.05). As previously reported for morphine (Hill 
et al., 2016), although tidal volume was maintained in the presence of oxycodone the 
duration of inspiration was prolonged whilst the depth of respiration was reduced (Fig. 1E, F 
& H). Tidal volume was maintained because the duration of inspiration was prolonged by an 
apneustic compensation (see also Hill et al., 2016). Mice did not appear to exhibit ribcage 
muscle stiffness during oxycodone treatment.  
 
Prior administration of the opioid receptor antagonist naloxone (1 mg.kg-1 i.p., 30 mins prior 
to opioid agonist) inhibited the respiratory depressant effects of both oxycodone (3 mg.kg-1) 
and morphine (10 mg.kg-1) whereas the selective -opioid receptor (DOPr) antagonist 
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naltrindole (20 mg.kg-1 i.p., 30 mins prior to opioid agonist) had no effect on the respiratory 
depressant effect of either opioid (Fig. 2A and B). Treatment with the -opioid receptor (KOPr) 
antagonist NorBNI (10 mg.kg-1 i.p.) 24 h prior to the opioid administration did not affect the 
respiratory depressant effect of oxycodone (3 mg.kg-1) or morphine (10 mg.kg-1)(Fig. 2A and 
B) but did however prevent the antinociceptive response to the KOPr agonist U69593 (20 
mg.kg-1 i.p.) in the tail flick latency assay (latencies to withdrawal - control 3.6 ± 0.9 s; U69593 
6.1 ± 0.5 s; NorBNI + U69593 3.3 ± 0.5 s (N = 6 in all groups) (U69593 vs control or NorBNI + 
U69593 P<0.05, One-way ANOVA with Bonferroni’s post-test, F=5.42, dfn=2, dfd=18) proving 
that the antagonist was active in these in vivo experiments. 
Development of tolerance to oxycodone and cross-tolerance to morphine following 
prolonged oxycodone administration. 
To induce tolerance with oxycodone we used a similar schedule of priming doses followed by 
pump implantation to that we have used previously for morphine and methadone (Withey et 
al., 2016). We examined three oxycodone treatment schedules - low dose, moderate dose 
and high dose (for details of the dosage regimes see Methods and Materials).  The plasma 
and brain levels of oxycodone measured on day 6 of treatment are given in Table 1. By day 6 
the respiratory rate of mice in each oxycodone treatment group was not different from that 
of saline-treated control mice (minute volume values (ml.min-1) 184 ± 12 saline-treated; 174 
± 17 low dose oxycodone; 175 ± 10 medium dose oxycodone; 186 ± 13 high dose oxycodone) 
(One-way ANOVA with Bonferroni’s post-test, F=0.214, dfn=3, dfd=28, P>0.05). Without 
removing the oxycodone-containing pump mice were then challenged with oxycodone (3 
mg.kg-1 i.p.) or morphine (10 mg.kg-1 i.p.) to assess the degree of tolerance that had been 
induced. Prolonged medium dose oxycodone treatment reduced the response to acute 
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oxycodone challenge by 68% (Fig. 3E & F). Prolonged low dose oxycodone treatment reduced 
the response to acute morphine challenge by 42% whereas prolonged medium and high dose 
oxycodone treatment decreased the response to acute morphine challenge by over 88% and 
80% respectively (Fig. 3 A-D). The reductions in the morphine challenge responses induced by 
the prolonged medium and high dose oxycodone treatments were not statistically different 
from each other. 
 
Ethanol and pregabalin reversal of tolerance induced by oxycodone  
We have previously reported that a single, low dose of ethanol reversed morphine-induced 
tolerance to respiratory depression in mice but did not reverse either the tolerance induced 
by prolonged methadone treatment or the blockade of morphine-induced respiratory 
depression produced by prolonged treatment with buprenorphine (Hill et al., 2016). Similarly, 
we have shown that a single dose of S-pregabalin reversed morphine-induced tolerance to 
respiratory depression in mice (Lyndon et al., 2017). We therefore examined the ability of 
ethanol and pregabalin to reverse tolerance induced by prolonged oxycodone treatment. To 
do this we used doses of ethanol (0.3 g.kg-1 i.p.) and pregabalin (20 mg.kg-1 i.p.) that do not 
depress respiration (Hill et al., 2016; Lyndon et al., 2017). 
After prolonged treatment with medium or high dose oxycodone, mice that received ethanol 
(0.3 g.kg-1 i.p.) simultaneously with the challenge dose of morphine (10 mg.kg-1) showed 
significantly greater respiratory depression compared to mice that received only morphine 
challenge following prolonged oxycodone treatment (Fig. 4A). indicating that ethanol had 
reversed the oxycodone-induced tolerance. This low dose of ethanol alone did not cause 
significant respiratory depression in medium or high dose oxycodone pump-implanted mice 
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(Fig. 4). Tolerance induced by the medium dose oxycodone treatment was reversed by 
ethanol to 84% of control. Tolerance induced by high dose oxycodone treatment was reversed 
to 55% of control.  
In mice that had received the medium dose oxycodone treatment acute administration of 
pregabalin (20 mg.kg-1 i.p.) partially restored the respiratory depressant effect of the 
challenge dose of morphine (to 55% of control)(Fig. 4A). Pregabalin alone did not cause 
significant respiratory depression in medium or high dose oxycodone pump-implanted mice 
(Fig. 4). In mice that had received the high dose oxycodone treatment the restoration of the 
respiratory depressant effect of morphine, when pregabalin was co-administered, did not 
reach statistical significance (Fig. 4B). 
We next examined whether ethanol and pregabalin would act additively to reverse tolerance 
induced by high dose oxycodone treatment. Oxycodone treated mice received an acute 
injection of pregabalin (20 mg.kg-1 i.p) and ethanol (0.3 g.kg-1 i.p.) along with morphine (10 
mg.kg-1 i.p.). With the combination of ethanol and pregabalin there was no greater reversal 
of oxycodone-induced tolerance than by ethanol alone (Fig. 4B). 
Reversal of oxycodone-induced tolerance by calphostin C and lack of additivity with 
ethanol 
There is substantial evidence for the role of PKC in desensitization of MOPrs by morphine and 
subsequent development of cellular tolerance on prolonged exposure to morphine (Bailey et 
al 2004; 2009a; 2009b; Levitt & Williams, 2012; Williams et al., 2013). Similarly, PKC has been 
shown to be involved in the development of tolerance to the antinociceptive and respiratory 
depressant effects of morphine (Smith et al., 2007; Withey et al., 2017). We therefore sought 
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to investigate the role of PKC in tolerance induced by oxycodone using calphostin C, a brain-
penetrant drug that inhibits both conventional and novel isoforms of PKC (Kobayashi et al., 
1989). 
Calphostin C (45 µg.kg-1 i.p.) by itself had no direct effect on respiration in näive mice nor did 
it alter the acute respiratory depressant effect of morphine (10 mg.kg-1) (Withey et al., 2017).  
However, in mice that had received the chronic medium dose oxycodone treatment an acute 
injection of calphostin C (45 µg.kg-1 i.p.) 30 min prior to an acute morphine challenge 
completely restored the respiratory depressant effect of the morphine challenge (Fig. 4A). 
This effect was not observed in oxycodone treated mice injected with the vehicle for 
calphostin (0.5% DMSO in saline) prior to the morphine challenge (data not shown). As with 
ethanol and pregabalin, calphostin C alone did not cause significant respiratory depression in 
medium dose oxycodone pump-implanted mice (Fig. 4). These data are consistent with 
calphostin C reversing oxycodone-induced tolerance to respiratory depression. In mice that 
had received the high dose oxycodone treatment the acute injection of calphostin C (45 µg.kg-
1 i.p.) resulted in partial reversal of oxycodone-induced tolerance (to 55% of control)(Fig. 4B).  
We next examined whether ethanol and calphostin C would act additively to reverse 
tolerance induced by high dose oxycodone treatment. Oxycodone treated mice received an 
acute injection of calphostin C (45 µg.kg-1 i.p) 30 min prior to administration of ethanol (0.3 
g.kg-1 i.p.) and morphine (10 mg.kg-1 i.p.). With the combination of ethanol and calphostin C 
there was no greater reversal of oxycodone-induced tolerance than by either drug alone (Fig. 
4B).  
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DISCUSSION 
The results of this study demonstrate that oxycodone, a prescription opioid and major drug 
of abuse, induces marked respiratory depression; that with prolonged oxycodone 
administration tolerance develops to this effect; and most interestingly that this tolerance is 
reversed by inhibition of PKC, by low dose ethanol, and by pregabalin. Thus, this study 
highlights the potential dangers of polydrug abuse when taking oxycodone either as a 
prescribed drug or as a drug of abuse. 
We observed that in the mouse oxycodone was more potent than morphine in depressing 
respiration. The depression of respiration by oxycodone was reversed by naloxone, but not 
significantly altered by the DOPr antagonist naltrindole nor by the KOPr antagonist NorBNI 
indicating that the effect was mediated through activation of MOPr. Yang et al., (2016) had 
reported that in MOPr knockout mice high doses of oxycodone (>40 mg.kg-1 s.c.) induced 
naltrindole-reversible antinociception.  
We have previously observed that tolerance to the respiratory depressant effects of 
morphine does develop, but does so more slowly than tolerance to antinociception (Hill et 
al., 2016). The present study demonstrates that for respiratory depression prolonged (6 day) 
exposure to oxycodone also results in tolerance to oxycodone as well as cross tolerance to 
morphine. The degree of cross tolerance to morphine observed increased as the oxycodone 
treatment was increased. Oxycodone is eliminated in the rodent more rapidly than morphine 
(Raehal and Bohn, 2011) which may explain why we needed to use higher doses of oxycodone 
than morphine to induce equivalent levels of tolerance (compare the levels of tolerance 
induced by oxycodone in this paper with those observed for morphine in Hill et al., 2016).  
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The tolerance to respiratory depression induced by oxycodone was reversed by calphostin C, 
a brain penetrant inhibitor of PKC (Kobayashi et al., 1989). The fact that calphostin C reversed 
oxycodone-induced tolerance after 6 days of oxycodone treatment, indicates that ongoing 
PKC activity is required to maintain oxycodone tolerance. We have previously reported that 
calphostin C reversed morphine- but not methadone-induced tolerance (Withey et al., 2017). 
Morphine and oxycodone have similar lower intrinsic agonist efficacy at MOPr for G protein 
activation whereas methadone has higher intrinsic efficacy (McPherson et al., 2011). The 
agonist efficacy of oxycodone and morphine is still sufficient, however, for them to induce 
both analgesia and respiratory depression in man. It appears likely therefore that PKC is 
involved in tolerance to lower efficacy MOPr agonists but not to higher efficacy agonists. 
Multiple isoforms of PKC (PKC-α, -γ and –ε) have been identified as mediators of tolerance to 
the antinociceptive actions of morphine (Smith et al., 2007). Of related interest, expression 
of constitutively active PKCα or PKCε isoforms in the pre-Bötzinger complex, a group of 
neurons involved in the generation of respiratory rhythm that are inhibited by MOPr agonists, 
increased the development of tolerance to respiratory depression induced by morphine, an 
effect that afforded increased protection from death by overdose (Lin et al., 2012). 
The potential for other non-opioid drugs to contribute to overdose deaths involving opioids 
has long been recognized (see Hickman et al., 2007). In the present study, we focused on two 
drugs, ethanol and pregabalin. Ethanol is frequently detected at post mortem along with 
oxycodone and other prescription opioids (Cone et al., 2004; Häkkinen et al., 2012). 
Pregabalin is also used in the treatment of severe pain states, sometimes in combination with 
opioids. It has recently become a drug of abuse popular with heroin users and increasingly 
associated with opioid overdose deaths (Häkkinen et al., 2014; Lyndon et al., 2017). In 
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England and Wales there has been a dramatic increase in acute drug deaths involving 
pregabalin and its congener, gabapentin, in recent years (Lyndon et al., 2017). Data for 2016 
reveal that in over 90% of deaths in which pregabalin or gabapentin was present at post 
mortem, an opioid was also present (Office for National Statistics, 2017).  
Ethanol is one of the most commonly co-abused drugs by opioid users, despite the long-
standing warning that ethanol and opioids pose a significant health risk when taken together 
(Karch and Drummer, 2001; Oliver et al., 2007). In mice, low doses of ethanol have previously 
been shown to reverse morphine-induced cellular tolerance (Llorente et al., 2013), 
antinociception tolerance (Hull et al., 2013) and tolerance to respiratory depression (Hill et 
al., 2016). Ethanol also reverses oxycodone-induced antinociception tolerance (Jacob et al., 
2017) as well as tolerance to respiratory depression as shown in this paper.  
Acute ethanol administration in mice at doses that reversed tolerance did not alter brain 
concentrations of either oxycodone (Jacob et al., 2017) or morphine (Hill et al., 2016) 
suggesting that ethanol reversal of tolerance to these opioids is not due to altered drug 
distribution or other pharmacokinetic changes. Reversal of oxycodone-induced tolerance by 
ethanol did not summate with the reversal induced by calphostin C. This may indicate that 
these two drugs act to reduce PKC activity. Attempts to demonstrate ethanol inhibition of 
PKC have produced mixed results. Reneau et al., (2011) demonstrated that ethanol (1 – 100 
mM) inhibited PKC activity in vitro by up to 40%, although we and others found less 
inhibition of PKC activity by ethanol (Slater et al., 1997; Rex et al., 2008; Llorente et al., 
2013). However, such in vitro studies using purified PKC are likely to be hindered by the 
absence of cofactors that are required for ethanol inhibition of the enzyme and also do not 
examine the initial translocation of PKC from the cytoplasm to the plasma membrane. 
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There have been several recent reports that gabapentin and pregabalin, are being misused 
with subsequent development of dependence (Mersfelder and Nichols, 2016, Papazisis and 
Tzachanis, 2014, Schjerning et al., 2016, Smith et al., 2016). Additionally, pregabalin misuse is 
increasingly observed to be associated with opioid use, in particular, heroin users report that 
pregabalin reinforces or enhances the rewarding effects of heroin (Bastiaens et al., 2016, Evoy 
et al., 2017, Grosshans et al., 2013, McNamara et al., 2015, Smith et al., 2015, Lyndon et al., 
2017). We have previously demonstrated that in mice, a dose of pregabalin that did not in 
itself depress respiration, reversed tolerance to respiratory depression induced by prolonged 
morphine treatment, thus increasing opioid-induced respiratory depression (Lyndon et al., 
2017). At higher doses pregabalin alone depressed respiration an effect that summated with 
that of morphine. In the present study, we have shown that pregabalin partially reversed 
tolerance to respiratory depression induced by oxycodone. We are not aware of any evidence 
to date that pregabalin or gabapentin directly inhibit PKC, but gabapentin has been shown to 
reduce PKC translocation to the plasma membrane in rat spinal cord (Zhang et al., 2015). 
However, the mechanism by which pregabalin reverses oxycodone tolerance remains to be 
elucidated. Our observation that pregabalin reverses oxycodone tolerance highlights the 
potential risk of concomitant use of pregabalin and oxycodone either in patients taking these 
drugs to treat pain states or in people misusing these drugs. 
CONCLUSIONS 
Our data provide compelling evidence for an interaction between ethanol or pregabalin and 
oxycodone to reverse tolerance to the respiratory depressant effects of oxycodone. We 
conclude from this study that ethanol or pregabalin reversal of tolerance to the respiratory 
Hill et al 
 
20 
 
depression induced by oxycodone may be an important contributing factor in deaths involving 
this drug.   
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Table 1. Plasma and brain levels of oxycodone following prolonged (6 d) treatments. 
 
Oxycodone 
treatment 
Low Medium High 
Plasma 
concentration 
(ng.mL-1) 
81 ± 8 284 ± 147 1670 ± 635 
Brain level (ng.g-1) 248 ± 126 426 ± 87 1703 ± 665 
N = 6 in all cases except the plasma concentration following medium oxycodone treatment 
where N = 5 (one sample lost) 
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Figure legends 
Figure 1. Depression of respiration by oxycodone and morphine. Oxycodone (1 and 3 mg.kg-
1, i.p.) and morphine (1 – 10 mg.kg-1, i.p.) dose-dependently depressed mouse respiration. 
Saline did not depress respiration. In A and C data are presented as minute volume whereas 
in B and D the level of respiratory depression seen following drug injection is expressed as a 
percentage change in the pre-drug minute volume baseline, calculated for each mouse 
individually before mean data were plotted. In E and F the effect of oxycodone on respiratory 
rate and tidal volume are shown. Data are from the same groups of mice as in A and B. In G 
the data in B and D have been recalculated and plotted as the area under curve (AUC). The 
AUC for the percentage change in minute volume has been calculated for each individual 
animal before the mean AUC has been calculated. The data were analyzed using a One-way 
ANOVA with Bonferroni’s comparison (F=12.6, dfn=4, dfd=30, P<0.05, N = 6 for all groups). In 
A - G data are expressed as mean ± SEM. In H are shown raw respiration traces recorded from 
a single mouse before and after administration of oxycodone (3 mg.kg-1, i.p.). The thin 
horizontal line indicates the point of pressure inflexion. On the respiration traces inspiration 
is downwards. *p<0.05, ns non significant; N=6 for all groups. 
Figure 2. Effect of opioid receptor antagonists on the depression of respiration by 
oxycodone and morphine. Naloxone (NLX; 1 mg.kg-1, i.p.), administered 30 min prior, 
markedly reduced the respiratory depression induced by oxycodone (3 mg.kg-1, i.p.) (F=18.82, 
dfn=3, dfd=24, P<0.05) and abolished that induced by morphine (10 mg.kg-1, i.p.) (F=34.57, 
dfn=3, dfd=24, P<0.05). Naltrindole (NLT; 20 mg.kg-1 i.p.), administered 30 min prior, had no 
effect on the respiratory depression induced by oxycodone or morphine. Treatment with 
NorBNI (10 mg.kg-1, i.p.) 24 h prior to opioid administration did not affect respiratory 
depression induced by oxycodone or morphine. Data are expressed as mean ± SEM and were 
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compared using a one-way ANOVA with Bonferroni’s comparison.  *p<0.05, ns non 
significant; N=6 for all groups. 
Figure 3. Tolerance to respiratory depression induced by prolonged oxycodone treatment. 
A, B and C show the depression of respiration induced by a challenge dose of morphine (10 
mg.kg-1 i.p.) in mice that had received prolonged low, medium or high dose oxycodone 
treatment. In D the area under the curve (AUC) for the percentage change in minute volume 
in A - C has been determined for each individual animal before the mean AUC has been 
calculated and compared to that observed in animals that had not received prolonged 
oxycodone treatment. The depression of respiration induced by the challenge dose of 
morphine (10 mg.kg-1 i.p.) was attenuated (F=29.63, dfn=4, dfd=35 P<0.05) by oxycodone 
pretreatment. E shows the depression of respiration induced by a challenge dose of 
oxycodone (3 mg.kg-1i.p.) in mice that had received prolonged medium oxycodone treatment. 
In F the area under the curve (AUC) for the percentage change in minute volume in E has been 
determined for each individual animal before the mean AUC has been calculated and 
compared to that observed in animals that had not received prolonged oxycodone treatment. 
The depression of respiration induced by the challenge dose of oxycodone (3 mg.kg-1i.p.) was 
attenuated (F=36.99, dfn=2, dfd=21 P>0.05 by oxycodone pretreatment. Data were analysed 
using a One-way ANOVA with Bonferroni’s comparison. *p<0.05, ns non significant; N=7 for 
all groups. In all graphs data are expressed as mean ± SEM. 
Figure 4. Reversal by ethanol, pregabalin and calphostin C of tolerance to respiratory 
depression induced by prolonged treatment with oxycodone. A. In mice that received 
prolonged treatment with medium dose oxycodone, administration of ethanol (EtOH: 0.3 
g.kg-1) (F=21.91, dfn=1, dfd=24, P<0.05), pregabalin (PG: 20 mg.kg-1) (F=32.58, dfn=1, dfd=24 
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P<0.05) or calphostin C (CC: 45 µg.kg-1) (F=15.99, dfn=1, dfd=24 P<0.05) with the acute 
morphine challenge resulted in greater depression of respiration than in mice challenged with 
morphine alone. Data are expressed as mean ± SEM and were compared using a two-way 
ANOVA with Bonferroni’s comparison.  * indicates p<0.05 compared to medium oxycodone 
treatment plus saline/morphine challenge. N=7 for all groups. B. Effect of ethanol (0.3 g.kg-1) 
(F=46.99, dfn=1, dfd=24 P<0.05), pregabalin (20 mg.kg-1) (F=0.99, dfn=1, dfd=24 p>0.05) or 
calphostin C (45 µg.kg-1) (F=46.94, dfn=1, dfd=24 P<0.05) in mice that had undergone the high 
dose oxycodone treatment. In mice receiving both ethanol and calphostin C or ethanol and 
pregabalin there was no greater effect than that seen with either drug alone i.e. additivity 
was not observed. In each graph the area under the curve (AUC) for the percentage change 
in minute volume has been determined for each individual animal before the mean AUC has 
been calculated. Data are expressed as mean ± SEM and were compared using a two-way 
ANOVA with Bonferroni’s comparison.   Statistical comparisons not indicated by a bar in B are 
as follows: * p<0.05 and ns p>0.05 compared to saline/morphine challenge; $ p<0.05 
compared to the ethanol + morphine challenge group. N=7 for all groups. 
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